Latest Surrozen News & Updates

See the latest news and media coverage for Surrozen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Surrozen

Biotechnology company developing Wnt-based regenerative therapies

surrozen.com
Headquarters
South San Francisco, United States
Company type
Private company
Number of employees
10–70

Last updated

Latest news about Surrozen

In short: Surrozen advanced its ophthalmology pipeline, secured a $5M milestone payment, and reported a $242M net loss for the 2025 fiscal year.

Company announcements

  • Surrozen

    Surrozen reports Q1 2026 financial results

    Cash at $106.9M. On track for SZN-8141 IND submission H2 2026. Net loss $127.5M.

  • Surrozen

    Surrozen reports Q4 and full-year 2025 financial results

    Pipeline advances with IND submission for SZN-8141 planned for H2 2026. Receives $5M milestone from Boehringer Ingelheim. Strengthens leadership. Cash at $89.2M; net loss $242M.

  • Surrozen

    Surrozen reports Q3 2025 financial results

    Cash stands at $81.3M. Appoints Andrew Maleki as CFO. Advances ophthalmology pipeline with IND for SZN-8141 planned in 2026.

  • Surrozen

    Surrozen reports Q2 2025 financial results

    Appoints Daniel Chao as VP of Clinical Development, forms Clinical Advisory Board, progresses ophthalmology pipeline, reports $90.4M cash.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Surrozen

Track Surrozen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.